304am永利集团|·主頁(歡迎您)

Be the most trusted biotech company

2024-05-27

Henlius Rituximab Receives Marketing Approval in Peru
2024-05-24

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
2024-05-22

The Supplemental Applications of HANDAYUAN(adalimumab injection) for the New Indications Approved by the NMPA
2024-05-21

Henlius to Release Latest Clinical Data of HLX22 at 2024 ESMO GI
2024-05-16

Henlius to Showcase at BIO 2024
2024-05-15

First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-05-14

Henlius lasofoxifene HLX78 IND Approved by NMPA
2024-05-10

Henlius Holds its first Scientific Advisory Board Meeting of 2024
2024-05-06

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA

1
...
3
4
5
6
7
8
9